H
H. J. Lambers Heerspink
Researcher at University Medical Center Groningen
Publications - 35
Citations - 1980
H. J. Lambers Heerspink is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Kidney disease & Diabetes mellitus. The author has an hindex of 15, co-authored 21 publications receiving 1684 citations. Previous affiliations of H. J. Lambers Heerspink include Vanderbilt University Medical Center.
Papers
More filters
Journal ArticleDOI
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts
Brad C. Astor,Kunihiro Matsushita,Ron T. Gansevoort,Marije van der Velde,Mark Woodward,Andrew S. Levey,Paul E. de Jong,Josef Coresh,Meguid El-Nahas,Kai-Uwe Eckardt,Bertram L. Kasiske,Jackson T. Wright,Lawrence J. Appel,Tom Greene,Adeera Levin,Ognjenka Djurdjev,David C. Wheeler,Martin J Landray,John N. Townend,Jonathan Emberson,Laura E Clark,Alison M. MacLeod,Angharad Marks,Tariq Ali,Nicholas Fluck,Gordon Prescott,David H. Smith,Jessica R. Weinstein,Eric S. Johnson,Micah L. Thorp,Jack F.M. Wetzels,Peter J. Blankestijn,A D van Zuilen,Vandana Menon,Mark J. Sarnak,Gerald J. Beck,Florian Kronenberg,Barbara Kollerits,Marc Froissart,Bénédicte Stengel,Marie Metzger,Giuseppe Remuzzi,Piero Ruggenenti,Annalisa Perna,H. J. Lambers Heerspink,Barry M. Brenner,Dick de Zeeuw,Peter Rossing,Hans-Henrik Parving,Priscilla Auguste,Kasper Veldhuis,Yaping Wang,Laura Camarata,Beverly Thomas,Tom Manley +54 more
TL;DR: Lower eGFR and more severe albuminuria independently predict mortality and ESRD among individuals selected for CKD, with the associations stronger for E SRD than for mortality.
Journal ArticleDOI
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
TL;DR: Dapagliflozin and hydrochlorothiazide effects on 24‐h blood pressure, body weight, plasma volume and glomerular filtration rate are compared to investigate whether the parallel occurring sodium loss would have diuretic‐like physiologic effects.
Journal ArticleDOI
A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus
Sara S. Roscioni,Dick de Zeeuw,Merel E. Hellemons,Harald Mischak,Petra Zürbig,S. J. L. Bakker,Ron T. Gansevoort,Henrik Reinhard,Frederik Persson,Maria Lajer,Peter Rossing,Peter Rossing,Peter Rossing,H. J. Lambers Heerspink +13 more
TL;DR: Analysis of a urinary biomarker set enables early renal risk assessment in patients with diabetes and suggests the role of urinary proteomics in the prevention of renal failure in diabetes.
Journal ArticleDOI
Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus
Michelle J Pena,H. J. Lambers Heerspink,Merel E. Hellemons,T. Friedrich,Guido Dallmann,Maria Lajer,Stephan J. L. Bakker,Ron T. Gansevoort,Peter Rossing,Peter Rossing,Dick de Zeeuw,Sara S. Roscioni +11 more
TL;DR: This work aimed to discover plasma and urine metabolites that predict the development of micro‐ or macroalbuminuria.
Journal ArticleDOI
Increased serum potassium affects renal outcomes : a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Yan Miao,Daniela Dobre,H. J. Lambers Heerspink,Barry M. Brenner,Mark E. Cooper,H. H. Parving,Shahnaz Shahinfar,D. E. Grobbee,Dick de Zeeuw +8 more
TL;DR: Treatment with the ARB losartan is associated with a high risk of increased serum potassium levels, which is in turn associated with an increased risk of renal outcomes in patients with type 2 diabetes and nephropathy.